News Breaks |
|
|
| December 9, 2012 |
| 12:26 EDT |  | ALNY | Alnylam presents new pre-clinical data on RNAi therapeutics
Alnylam Pharmaceuticals announced that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemoglobinopathies at the 54th American Society of Hematology Annual Meeting being held December 8-11, 2012 in Atlanta. Alnylam scientists presented data showing that ALN-TMP, an RNAi therapeutic targeting Tmprss6, leads to disease modifying effects, including a correction in globin gene expression, in a model of ß-thalassemia. These studies were conducted in collaboration with Boston Children’s Hospital. Alnylam’s program in hemoglobinopathies comprises part of its ‘Alnylam 5x15™’ product strategy, by which the company aims to advance five programs in clinical development, including programs in advanced stages, by the end of 2015. |
|
|
News For ALNY From The Last 14 Days Check below for free stories on ALNY the last two weeks. |
|
|
| May 24, 2013 |
| 10:04 EDT |  | ALNY | On The Fly: Analyst Initiation Summary
 Subscribe for More Information |
|
| 05:47 EDT | | ALNY | Alnylam initiated with a Buy at Deutsche Bank
Subscribe for More Information |
|
| May 22, 2013 |
| 11:53 EDT |  | ALNY | High option volume stocks: UAN MYL ALNY SKS XIDE
Subscribe for More Information |
|
| 07:28 EDT |  | ALNY | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link |
|
| May 17, 2013 |
| 08:04 EDT | | ALNY | Alnylam announces proof-of-concept data from RNAi program
Subscribe for More Information |
|
| May 16, 2013 |
| 07:29 EDT | | ALNY | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 14, 2013 |
| 08:43 EDT |  | ALNY | Alnylam has multiple upcoming positive catalysts, says JMP Securities
JMP Securities believes that Alnylam will have multiple positive data catalysts over the next two months. The firm thinks that upcoming data and presentations will enhance the company's positioning and perception of its pipeline, and it keeps an Outperform rating on the shares. |
|
|
|
|
|
